CRSP

MKT CAP:$5B

CRISPR Therapeutics AG

Market Cap

$5B

Healthcare·Biotechnology·🇨🇭 Switzerland·NASDAQ

Healthcare·Biotechnology·🇨🇭·NASDAQ

Stock Price

$55.18+$1.41 (+2.62%)

Apr 23, 2026

Company Details

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) plat...

CEO

Samarth Kulkarni

IPO Date

Oct 19, 2016

Website

www.crisprtx.com

Key Metrics TTM

Revenue

$3M

-92.7% YoY

Net Income

-$582M

EPS (Diluted)

-$6.52

Free Cash Flow

-$346M

Revenue / Share

$0.03

Gross Margin

-8560.0%

Operating Margin

-25384.7%

Net Margin

-22215.4%

FCF Margin

-13213.4%

P/S

1865.6x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Feb 12, 2026

$4MEPS -$6.47

Q4 2025

Feb 12, 2026

$864.0K-97.5%EPS -$1.37

Q3 2025

Nov 10, 2025

$889.0KEPS -$1.17

Q2 2025

Aug 4, 2025

$0-100.0%EPS -$2.40

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$178.0K	-$30M	-$176M
Q2 22	$158.0K	-$34M	-$183M
Q3 22	$94.0K	-$39M	-$182M
Q4 22	$6.0K	-$7M	-$132M
Q1 23	$100M	$58M	-$64M
Q2 23	$70M	$25M	-$95M
Q3 23	$0	-$23M	-$132M
Q4 23	$200M	$180M	$70M
Q1 24	$504.0K	-$51M	-$141M
Q2 24	$517.0K	-$56M	-$151M
Q3 24	$0	-$11M	-$110M
Q4 24	$35M	$35M	-$65M
Q1 25	$865.0K	-$57M	-$148M
Q2 25	$0	-$45M	-$229M
Q3 25	$889.0K	-$64M	-$132M
Q4 25	$864.0K	-$59M	-$155M

Valuation

Quarter	P/S	P/E
Q1 22	5.4x	14.3x
Q2 22	5.8x	19.4x
Q3 22	6512.6x	—
Q4 22	8423.5x	—
Q1 23	35.7x	—
Q2 23	26.3x	—
Q3 23	19.9x	—
Q4 23	13.9x	—
Q1 24	21.4x	—
Q2 24	22.9x	—
Q3 24	20.0x	—
Q4 24	91.7x	—
Q1 25	80.4x	—
Q2 25	116.5x	—
Q3 25	151.1x	—
Q4 25	1794.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$135M	-$151M
Q2 22	-$142M	-$152M
Q3 22	-$105M	-$111M
Q4 22	-$113M	-$120M
Q1 23	$9M	$6M
Q2 23	-$133M	-$137M
Q3 23	-$40M	-$42M
Q4 23	-$96M	-$97M
Q1 24	$110M	$109M
Q2 24	-$96M	-$96M
Q3 24	-$107M	-$107M
Q4 24	-$50M	-$50M
Q1 25	-$54M	-$54M
Q2 25	-$114M	-$114M
Q3 25	-$85M	-$85M
Q4 25	-$93M	-$93M

Capital Expenditures

Quarter	CapEx
Q1 22	$15M
Q2 22	$10M
Q3 22	$6M
Q4 22	$6M
Q1 23	$3M
Q2 23	$4M
Q3 23	$2M
Q4 23	$738.0K
Q1 24	$721.0K
Q2 24	$707.0K
Q3 24	$219.0K
Q4 24	$254.0K
Q1 25	$206.0K
Q2 25	$117.0K
Q3 25	$74.0K
Q4 25	$517.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-51.9%	+62.9%
Q2 22	-21.8%	+59.8%
Q3 22	-100.0%	+32.6%
Q4 22	-98.2%	+1.8%
Q1 23	+56079.8%	-6.6%
Q2 23	+44203.8%	-9.9%
Q3 23	-100.0%	-27.4%
Q4 23	+3333233.3%	-0.9%
Q1 24	-99.5%	-14.2%
Q2 24	-99.3%	-8.1%
Q3 24	—	-16.8%
Q4 24	-82.5%	-23.6%
Q1 25	+71.6%	+5.8%
Q2 25	-100.0%	+51.1%
Q3 25	—	+20.7%
Q4 25	-97.5%	+56.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$26M	14463.5%
Q2 22	$25M	15729.1%
Q3 22	$25M	26111.7%
Q4 22	$23M	380083.3%
Q1 23	$21M	20.9%
Q2 23	$22M	31.1%
Q3 23	$20M	—
Q4 23	$18M	9.2%
Q1 24	$19M	3850.2%
Q2 24	$24M	4578.7%
Q3 24	$22M	—
Q4 24	$22M	62.7%
Q1 25	$20M	2336.6%
Q2 25	$18M	—
Q3 25	$17M	1867.7%
Q4 25	$18M	2092.1%

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$118M	$28M
Q2 22	$123M	$26M
Q3 22	$117M	$27M
Q4 22	$104M	$21M
Q1 23	$100M	$22M
Q2 23	$102M	$19M
Q3 23	$91M	$18M
Q4 23	$95M	$16M
Q1 24	$71M	$18M
Q2 24	$75M	$19M
Q3 24	$82M	$17M
Q4 24	$82M	$18M
Q1 25	$72M	$19M
Q2 25	$166M	$19M
Q3 25	$59M	$17M
Q4 25	$78M	$18M

Revenue Segments

Quarter	Collaboration Revenue	Grant
Q2 22	$158.0K	—
Q3 22	$94.0K	—
Q4 22	$6.0K	—
Q1 23	$100M	—
Q2 23	$70M	—
Q4 23	$200M	—
Q1 24	—	$504.0K
Q2 24	—	$517.0K
Q3 24	—	$602.0K
Q1 25	—	$865.0K
Q2 25	—	$892.0K
Q3 25	—	$889.0K
Q4 25	—	$864.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$684M	$1.5B	$2.2B
Q2 22	$497M	$1.6B	$2.1B
Q3 22	$494M	$1.4B	$1.9B
Q4 22	$212M	$1.6B	$1.8B
Q1 23	$344M	$1.5B	$1.9B
Q2 23	$445M	$1.3B	$1.8B
Q3 23	$528M	$1.2B	$1.7B
Q4 23	$389M	$1.3B	$1.7B
Q1 24	$707M	$1.4B	$2.1B
Q2 24	$484M	$1.5B	$2.0B
Q3 24	$226M	$1.7B	$1.9B
Q4 24	$298M	$1.6B	$1.9B
Q1 25	$235M	$1.6B	$1.9B
Q2 25	$197M	$1.5B	$1.7B
Q3 25	$290M	$1.6B	$1.9B
Q4 25	$355M	$1.6B	$2.0B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	77M	+1.1%	+9.9%
Q2 22	78M	+0.5%	+3.3%
Q3 22	78M	+0.7%	-3.0%
Q4 22	78M	+0.4%	+2.7%
Q1 23	79M	+0.4%	+2.0%
Q2 23	79M	+0.5%	+2.0%
Q3 23	79M	+0.4%	+1.8%
Q4 23	81M	+2.4%	+3.8%
Q1 24	82M	+0.6%	+4.0%
Q2 24	85M	+3.8%	+7.4%
Q3 24	85M	+0.4%	+7.3%
Q4 24	85M	+0.3%	+5.1%
Q1 25	86M	+0.6%	+5.1%
Q2 25	87M	+1.3%	+2.5%
Q3 25	91M	+4.9%	+7.1%
Q4 25	90M	-1.5%	+5.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$376	473
Q2 22	$334	473
Q3 22	$199	473
Q4 22	$13	458
Q1 23	$218.3K	458
Q2 23	$152.8K	458
Q3 23	$0	458
Q4 23	$491.4K	407
Q1 24	$1.2K	407
Q2 24	$1.3K	407
Q3 24	$0	407
Q4 24	$89.1K	393
Q1 25	$2.2K	393
Q2 25	$0	393
Q3 25	$2.3K	393
Q4 25	$4	200K

Revenue / Employee